重组人血管内皮抑素联合化学疗法治疗晚期非小细胞肺癌临床观察

目的探讨紫杉醇、顺铂联合重组人血管内皮抑素(恩度)一线治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法 53例晚期NSCLC患者随机分组:26例接受紫杉醇、顺铂联合恩度(试验组)治疗,27例接受紫杉醇、顺铂治疗(对照组),每2个周期行影像学评价疗效。结果试验组和对照组的有效率为30.8%vs 22.2%(P<0.01),疾病控制率为61.5%vs 44.4%(P<0.01),试验组中位进展时间为7.5个月,对照组中位进展时间为4个月,差异显著(P<0.01)。结论 YH-16联合TP方案与单独TP比较,能进一步增加疗效。

Rh-endostatin (YH-16) in combination with chemotherapy for advanced non-small cell lung cancer: A clinical observation

Objective To evaluate the therapeutic response and adverse reaction of the combination of rh-endostatin(YH-16) with paclitaxel plus cisplatin(YH-16 + TP) in patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 53 patients with advanced NSCLC were randomly divided into two groups.Twenty-six patients with NSCLC in the treatment group administrated with YH-16 15 mg/d(day 1 to day 14),PTX 70 mg/m2(day 1 and 8),and DDP 40 mg/m2(day 2 to day 3),every 21 days for two to three cycles.In contrast,27 patients in the control group revived a combination therapy of PTX 70 mg/m2(day 1 and 8) and DDP 40 mg/m2(day 2 to day 3) for the same therapeutic cycles.Results The treatment group showed a response rate(RR) of 30.8% versus control group of 22.2%(P<0.001).The disease control rate(DCR) was 61.5% and 44.4% in two groups,respectively.Patients receiving the triple therapy had a median TTP of 7.5 months compared with 4.0 months in patients receiving bi-therapy(control)(P<0.001).Conclusion Significant efficacy against NSCLC is observed in YH-16 in the combination with paclitaxel plus cisplatin compared to bi-therapy of paclitaxel and cisplatin.However,further clinical studies were needed to assess the activity of the triple therapy.